Guest View
User: Pass: | become a member


SurModics Announces Agreement to Sell Pharmaceutical Assets for $30M

Courtesy of Benzinga.



SurModics, Inc. (Nasdaq: SRDX) announced last night that it has entered into a definitive agreement to sell its SurModics Pharmaceuticals assets to Evonik Industries AG for $30 million in cash. Under the Asset Purchase Agreement, the entire portfolio of products and services of SurModics Pharmaceuticals, including the Company’s cGMP development and manufacturing facility located in Birmingham, Alabama, will be acquired by Evonik.

This grants Evonik ownership of SurModics’ parenteral dosage technology platforms and services and bioresorbable lactide-glycolide polymers business.

Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!




You must be logged in to make a comment.
You can sign up for a membership or get a free SWW trial or log in.

Dashboard

 Sector Performances (Today)

 Thermal Imaging

Medical0.34 %
 
Basic Materials0.24 %
 
Consumer Discretionary0.16 %
 
Retail-Wholesale0.15 %
 
Consumer Staples0.13 %
 
Utilities0.12 %
 
Construction0.11 %
 
Transportation0.08 %
 
Aerospace0.01 %
 
Business Services-0.07 %
 
Multi-Sector Conglomerate-0.08 %
 
Finance-0.10 %
 
Industrial Products-0.27 %
 
Auto-Tires-Trucks-0.33 %
 
Computer and Technology-0.67 %
 
Oils-Energy-0.87 %